Analysts expected Eli Lilly’s Forteo to be the big challenge standing in the way of new Radius bone drug Tymlos. But Express Scripts apparently has other ideas. On Monday, the PBM giant said Forteo ...
TYMLOS ® demonstrated a lower incidence of hip fracture and non-vertebral fracture compared to teriparatide in women with osteoporosis 50 years and older (n=43,352) in this analysis of real-world data ...
Labatec Pharma SA: Switzerland and the MENA region including Bahrain, Iraq, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, UAE, Algeria, and Morocco Pharmbio Korea Inc.: South Korea Biosidus: Colombia, ...
(MENAFN- GlobeNewsWire - Nasdaq) itemprop="articleBody">-Post-hoc analysis suggests abaloparatide may be useful in the treatment of women with postmenopausal osteoporosis and concurrent osteoarthritis ...
Radius Health Inc. won FDA approval, albeit mildly delayed, of injected Tymlos (abaloparatide) for postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic ...
WALTHAM, Mass., March 17, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing ...
Results showed that treatment with abaloparatide for 12 months resulted in significant increases in bone mineral density compared with placebo. The Food and Drug Administration (FDA) has approved ...
BOSTON, June 08, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided an update on the global business expansion of TYMLOS (abaloparatide) subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results